Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial

Ascendis Pharma A/S (NASDAQ:ASND) is one of the 7 Fastest Growing European Stocks to Invest In. On March 17, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced positive Week 52 topline results from the Phase 2 New InsiGHTS trial evaluating once-weekly TransCon hGH against daily somatropin in prepubertal children with Turner syndrome. At Week 52, annualized height velocity was similar between the two groups, with an LS mean of 9.05 cm/year for TransCon hGH-treated children versus 9.04 cm/year for daily somatropin. The company also said TransCon hGH showed a safety and tolerability profile similar to daily somatropin through follow-up of up to 143 weeks, with adverse events reported as mild to moderate and no discontinuations due to adverse events.

On March 16, 2026, Jefferies assumed coverage of Ascendis Pharma A/S (NASDAQ:ASND) with a Buy rating and a $290 price target, describing the company as a “two-engine growth story” with Yorvipath on a “hot growth trajectory” and Yuviwel positioned to “disrupt” achondroplasia in the near term.

A medical technician holding the instruments in her hands

On the same day, the company announced new data from its pivotal ApproaCH trial showing that children with achondroplasia treated with once-weekly TransCon CNP maintained growth improvements through Week 104, with further gains in body proportionality during the second year of treatment. Ascendis said TransCon CNP, approved by the U.S. FDA in February 2026 under the trade name YUVIWEL, remains under review by the European Medicines Agency, with a decision expected in the fourth quarter of 2026.

Ascendis Pharma A/S (NASDAQ:ASND) develops TransCon-based therapies for unmet medical needs.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.